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Abstract
Purpose Ocular mucous membrane
pemphigoid (OcMMP) is a sight-threatening
autoimmune disease in which referral to
specialists units for further management is a
common practise. This study aims to describe
referral patterns, disease phenotype and
management strategies in patients who
present with either early or established
disease to two large tertiary care hospitals
in the United Kingdom.
Patients and Methods In all, 54 consecutive
patients with a documented history of
OcMMP were followed for 24 months. Two
groups were deﬁned: (i) early-onset disease
(EOD:o3years, n¼26, 51 eyes) and
(ii) established disease (EstD:45years,
n¼24, 48 eyes). Data were captured at ﬁrst
clinic visit, and at 12 and 24 months follow-up.
Information regarding duration, activity and
stage of disease, visual acuity (VA),
therapeutic strategies and clinical outcome
were analysed.
Results Patients with EOD were younger and
had more severe conjunctival inﬂammation
(76% of inﬂamed eyes) than the EstD group,
who had poorer VA (26.7%¼VAo3/60,
Po0.01) and more advanced disease. Although
40% of patients were on existing
immunosuppression, 48% required initiation
or switch to more potent immunotherapy.
In all, 28% (14) were referred back to the
originating hospitals for continued care.
Although inﬂammation had resolved in 78%
(60/77) at 12 months, persistence of
inﬂammation and progression did not differ
between the two phenotypes. Importantly,
42% demonstrated disease progression in the
absence of clinically detectable inﬂammation.
Conclusions These data highlight that
irrespective of OcMMP phenotype, initiation
or escalation of potent immunosuppression is
required at tertiary hospitals. Moreover, the
conjunctival scarring progresses even when
the eye remains clinically quiescent. Early
referral to tertiary centres is recommended to
optimise immunosuppression and limit
long-term ocular damage.
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Introduction
Mucous membrane pemphigoid (MMP) is a
potentially fatal autoimmune disease
1 with a
mortality usually secondary to aero-digestive
tract stricture formation, quoted as 0.029 per
100000 in the United States during 1992–2002.
2
Although the condition is associated with skin
and mucous membrane involvement including
the oral cavity, oesophagus, trachea and
genitals,
3 ocular manifestations of MMP
(OcMMP) are deﬁned as ‘high risk’ and can be
blinding.
3 Management strategies are aimed at
early diagnosis together with the prevention of
both life- and sight-threatening complications
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Ythrough the removal of factors that precipitate
inﬂammation, careful immunomodulation and/or
surgical intervention.
The course of ocular disease is variable, and
determining disease activity and progression represents
a major challenge.
4 Patients are often diagnosed at an
advanced stage of disease or with an acutely inﬂamed
eye,
5,6 which if left untreated, may result in an
acceleration of disease progression that can be
unresponsive to pharmacological manipulation.
7,8 In
order to delay or arrest this process, early intervention
with systemic immunosuppression is required,
3–5,9–12
usually by adopting either a validated stepladder
approach based on the severity of disease activity,
10,13 or
the primary use of oral cyclophosphamide,
11 both
inducing long-lasting remission.
In the United Kingdom, streams of hospital referral are
to tertiary care services specialising in the management
of OcMMP, from ophthalmologists practicing in
secondary care, directly from the primary care services
such as general (family) practitioners or optometrists,
and from dermatologists/oral medicine specialists
referring patients for screening with a diagnosis of MMP
at extra-ocular sites. Although the possibility of a referral
bias of patients with a more severe phenotype is
recognised,
11 there is limited information regarding the
clinical features of patients with early or established
disease who present to specialised services, whether
these patients require continued tertiary care, or are
discharged back to their referring unit.
Amongst our patient cohorts, we have noted that
delaying referral of patients with OcMMP to our
specialist hospitals seemed to augment a clinical
phenotype that is refractory or only partially responsive
to therapeutic intervention. The aim of this study,
therefore, was to characterise referral patterns and
disease phenotype (including activity, staging and
progression) in patients with OcMMP who present either
early or late according to duration of symptoms, to the
two largest tertiary specialist hospitals in the United
Kingdom, and the strategies employed to manage these
patients.
Materials and Methods
Study population
A total of 54 consecutive patients with a documented
history of OcMMP referred to dedicated ocular surface
disease clinics over a 3-year period at the two largest
specialist referral centres in the United Kingdom,
Moorﬁelds Eye Hospital (MEH, London, UK) and the
Birmingham and Midland Eye Centre (BMEC,
Birmingham, UK) were identiﬁed from electronic
databases and followed for 24 months. Patients were
stratiﬁed according to duration of symptoms, where
symptoms were deﬁned as redness, tearing, burning,
decreased vision or foreign body sensation.
14 The
frequency distribution of the duration of disease deﬁned
two groups straddling either side of the median (1460
days (4 years); Supplementary Figure 1). Group1 (n¼26,
51 eyes) consisted of patients with o1095 days (o3
years) history and was termed the ‘early-onset’ disease
(EOD) group, whereas group 2 (n¼24, 48 eyes)
comprised patients with 41825 days (45 years) history
and was termed the ‘established’ disease (EstD) group.
Four patients had a duration of symptoms that fell on the
median (4 years), and these patients were excluded from
further analysis. The study was conducted following
ethical approval and conformed to the tenets of the
Declaration of Helsinki.
Diagnosis
Diagnosis of OcMMP was based on clinical ﬁndings
characteristic for the disease, namely progressive
conjunctival cicatrisation in the absence of other causes of
conjunctival scarring. If patients did not had a previous
positive tissue biopsy, a conﬁrmatory perilesional
conjunctival and/or oral mucosal biopsy for direct
immunoﬂuorescence was undertaken. A positive result
was deﬁned as linear deposition of immunoglobulin G,
A or complement (C3) along the basement membrane
zone.
3 If typical clinical characteristics were evident, a
negative result did not exclude the diagnosis
10,14–16
because of the recognition of a subgroup of ocular
patients who have ocular features consistent with
OcMMP but have a negative biopsy.
15,17 In accordance
with the ﬁrst international consensus, a positive indirect
immunoﬂuorescence was not an essential requirement
for diagnosis.
3
Study design
Data were captured at presentation, immediately
following ﬁrst consultation, at 12 and 24 months for both
the EOD and EstD groups. Visual acuity (VA) was
classiﬁed as good (6/6–6/18), or in accordance with the
WHO deﬁnitions of ‘visual impairment’ (o6/18–6/60),
‘severe visual impairment’ (o6/60) and ‘blind’ (o3/60).
Disease activity was based upon the degree of
conjunctival inﬂammation: absent, mild, moderate or
severe (including inﬂammation in all four quadrants,
limbitis and/or conjunctival ulceration).
18 Stage of
disease and progression was determined by using the
staging systems described by Mondino and Brown
(I, 0–25%; II, 25–50%; III, 50–75%; IV, 75–100% loss of
inferior fornix)
7 and Foster (I, subconjunctival scarring
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Eyeand ﬁbrosis; II, fornix foreshortening of any degree;
III, presence of any degree of symblepharon; IV, end-
stage cicatricial pemphigoid).
19 Progression was deﬁned
as an advance in either Mondino or Foster staging
criteria. Immunosuppression strategies used a ‘step–
ladder’ approach as previously described (Figure 1).
13
Information regarding surgical intervention was also
recorded.
Statistical analysis
Statistical analysis was by SPSS 16.0 for Macintosh and
14.0 for Windows (SPSS, Chicago, IL, USA; 2006), and
Prism version 5.0 for Macintosh (GraphPad Software,
CA, USA; 2008) using Fishers-exact test, McNemar’s test
and Kendall’s t-b for rank correlations. Continuous
variables were analysed by non-parametric tests
(Mann–Whitney U-test). Data were collected on all eyes
and comparisons were undertaken between the worst
affected eye for cross-sectional analysis of inﬂammation/
ﬁbrosis and the better-seeing eye for VA. When
determining disease progression, comparisons were
undertaken between patients (either one or both eyes).
In order to determine whether changes seen at differing
time points were signiﬁcant rather than as a result of a
change in the cohort (eg, because of the patients being
discharged back to the referring hospital or missing
data), longitudinal analysis of the same eye was
undertaken. Owing to the referral of patients back to the
originating physician, the sample sizes at the three time
points differ and percentages rather than absolute counts
are therefore reported.
Results
Demographic information and referral patterns
The geographical origin of our patient cohort is
illustrated in Figure 2, where the furthest referral was
from Newquay in Cornwall to MEH (238 miles).
Associated patient demographics and subgroup
stratiﬁcation (EOD vs EstD) is detailed in Table 1. The
EOD group was younger than the EstD group (62 (32–82)
vs 69 (39–91) years (median, range; P¼0.02)). In all, 19
patients (37 eyes) from the EOD and 16 patients (32 eyes)
from the EstD were followed for the full 24 months. Of
the 15 patients, not reviewed at 24 months, 1 patient in
the EstD group died before 12 months follow-up and
14 (28%) were referred back to the referring hospital.
Of these, 11 had no clinically detectable inﬂammation at
their last visit before discharge from the tertiary centre,
2 had mild inﬂammation, which continued to be
monitored and treated at the local referring hospital, and
1 patient repeatedly failed to attend for follow-up despite
recall. The remaining cohort (EOD 19; EstD 16) consisted
of patients with more severe ocular disease.
Biopsies
A total of 87.2% (34/39) of patients, who underwent a
biopsy, were direct immunoﬂuorescence (DIF) positive.
By contrast, indirect immunoﬂuorescence studies were
positive in only 34.8% (8/23) of tested individuals, all of
whom were also DIF positive (Table 1). Although ﬁve
Figure 1 Immunosuppression strategies (based on Rauz et al
13).
A step–ladder approach to treatment with agents having the
fewest side effects to those that have the greatest side effects is
adopted according to disease activity (mild, moderate or severe),
which is used to guide therapy. Dapsone (25–50mg twice a day)
or sulphapyridine (500mg twice a day) can be used for mild
inﬂammation; azathioprine (1–2.5mg/kg/day) or mycopheno-
late mofetil (500–1000mg twice a day if intolerant to azathiopr-
ine) may be added or substituted for persistent disease. Severe
inﬂammatory disease is treated with cyclophosphamide
(1–2mg/kg/day) and adjuvant prednisolone (1mg/kg/day
with or without supplementary loading doses of 1g intravenous
methylprednisolone preceding oral therapy) for up to 3 months
until the optimal effects of cyclophosphamide have taken effect.
Patients with refractory disease are managed through intrave-
nous immunoglobulin or ‘biological’ agents such as anti-CD 20
(rituximab) or anti-TNFa therapy.
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Eye(12.8%) patients were biopsy negative, these patients had
clinical features consistent with OcMMP in the absence of
other causes of progressive conjunctival scarring.
Ten patients in total did not undergo a conjunctival
biopsy: seven patients were of advanced age (480 years)
with co-morbidities in which systemic immunosuppression
was contraindicated; and the remaining three patients had
end-stage disease (deﬁned as Mondino/Foster stage 4)
in which the sensitivity of a positive DIF conjunctival
biopsy is low due to physical destruction of the basement
membrane zone architecture.
15
Extra-ocular features
Extra-ocular mucocutaneous involvement was present in
52% (26/50) of patients at presentation (62% (16/26) of
the EOD group; 42% (10/24) of EstD group; P¼0.257;
Table 1). A total of 18% (9/50) patients had a history of
skin involvement and this was more frequently reported
in the EstD group (29.2% (7/24)) than the EOD group
(7.7% (2/26)). Conversely, oral involvement was more
common in the EOD group (57.7% (15/26)) compared
with 20.8% (5/24) in the EstD group (P¼0.01).
Visual acuity
After excluding other causes of reduced vision such as
cataract, age-related macular degeneration, glaucoma and
diabetic retinopathy (n¼14, EOD 5; EstD 9) at presentation,
95% (20/21) of patients in the EOD group and 60% (19/15)
in the EstD group had a Snellen VA of between 6/6 and
6/18 in the better-seeing eye. Only patients in the EstD
group were severely visually impaired (o3/60, 26.7%
(4/15)) and overall VAwas signiﬁcantly worse for the EstD
group (Po0.01; Kendal t-b; Table 1).
Inﬂammation
At presentation, 53% (50/94) of all eyes had clinical
evidence of conjunctival inﬂammation where the
majority (76% (38/50 eyes)) were in the EOD group
(Po0.001) when comparing the worst affected eye
(Figure 3a). Patients with moderate/severe inﬂammation
were also more likely to have EOD. By 12 months follow-up
(Figure 3a), inﬂammation had resolved in 78% (60/77) of
all eyes (EOD¼83% (35/42) vs EstD¼71% (25/35),
P¼0.917) and there were no patients with residual
severe conjunctival inﬂammation. These data were
endorsed by McNemar’s longitudinal analysis, showing
a signiﬁcant reduction in inﬂammation in the EOD
(Po0.001) compared with the EstD group (P¼1.0).
A recalcitrant group of patients with persistent
inﬂammation not responsive or only partially responsive to
treatment was identiﬁed in 29.9% (20/67) of eyes examined
at 24 months. Interestingly, the persistence of inﬂammation
was independent of group phenotype (EOD¼27% (10/37)
vs EstD¼33.3% (10/30), P¼0.967; Figure 3a).
Figure 2 Map containing ordnance survey data (& Crown copyright and database right 2010) showing the combined geographical
distribution of referrals (!) to the two tertiary referral hospitals: Moorﬁelds Eye Hospital, London, UK (circled, L) and the
Birmingham and Midland Eye Centre, Birmingham, UK (circled, B). The furthest referral was for Newquay, Cornwall to Moorﬁelds
(238 miles).
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Eyes in the EstD group had more severe conjunctival
ﬁbrosis at presentation (Figures 3b and c) gauged by
staging systems described by both Mondino (stage IV:
EOD¼5% (2/40) vs EstD¼39.5% (17/45), Po0.001) and
Foster (stage IV: EOD¼3.9% (2/51) vs EstD¼13%
(16/46), Po0.035). At 12 months, the EstD group
demonstrated signiﬁcantly advanced stage of disease,
irrespective of staging system used (Figures 3b and c),
despite a total of 20.8% of all eyes having progressed
according to both Mondino and Foster systems.
There was no signiﬁcant difference when comparing
progression (deﬁned by worsening of clinical stage of
disease in at least one eye) amongst patients in both the
groups, neither between presentation and at 12 months
(Mondino: EOD¼33.3% (4/12) vs EstD¼23.1% (3/13),
P¼0.67; Foster: EOD¼18.2% (4/22) vs EstD¼38.9%
(7/18) P¼0.173), nor during the subsequent 12 to 24
months follow-up period (Mondino: EOD¼53.8% (4/22)
vs EstD¼16.7% (2/12), P¼0.10; Foster: EOD¼23.5%
(4/17) vs EstD¼28.6% (4/14) P¼1.0; Fishers exact test).
Progression and the presence of conjunctival
inﬂammation
Differences in the rates of progression (deﬁned by an
advance in Mondino or Foster staging) were stratiﬁed
Table 1 Patient demographics and characteristics
All patients Early-onset disease Established disease P-value
Total no. of patients 50 26 24 F
Total no. of eyes 99 51 48 F
Male: female (% female) 23:27 (54) 11:15 (58) 12:12 (50) F
Median age (years; range) 67 (32–91) 62 (32–82) 69 (39–91) P¼0.02
Median duration of symptoms (years; range) 3 (0–41) 1.5 (0–3) 14 (5–41) Po0.0001
Patient follow-up (eyes)
12 months 43 (85) 23 (45) 20 (40) F
24 months 35 (69) 19 (37) 16 (32) F
No. of patients discharged back to referring hospital
a
Total number discharged 14 7 7 F
12 months follow-up 4 1 3 F
24 months follow-up 10 6 4 F
Biopsy
b
DIF positive 87.2% (34/39) 92% (23/25) 78.6% (11/14) P¼0.33
IIF positive
c 34.8% (8/23) 42.9 % (6/14) 2.2% (2/9) P¼0.4
Extraocular mucocutaneous involvement
All mucocutaneous tissues 52% (26/50) 62% (16/26) 42% (10/24) P¼0.26
Skin 18% (9/50) 7.7% (2/26) 29.2% (7/24) F
Oral 40% (20/50) 57.7% (15/26) 20.8% (5/24) P¼0.01
Visual acuity
d
Normal: 6/6 to 46/18 80.6% (29/36) 95.2% (20/21) 60% (9/15) P¼0.007
Visual impairment: o6/18 to 6/60 8.3% (3/36) 4.8% (1/21) 13.3% (2/15)
Severe visual impairment: 6/60 to 3/60 0% (0/36) 0% (0/21) 0% (0/15)
Blind: o3/60 11.1% (4/36) 0% (0/21) 26.7% (4/15)
Excluded due to other causes
d 28% (14/50) 19% (5/26) 38% (9/24)
Abbreviations: DIF, direct immunoﬂuorescence; IIF, indirect immunoﬂuorescence.
aFollow-up: one patient from the established disease group died before 12 months follow-up, and one from the established disease group failed to attend
between 12 and 24 months, and was referred back to their local hospital for continuing care.
bTen patients in total did not undergo a conjunctival biopsy (seven patients with advanced age (480 years) and immunosuppression was systemically
contraindicated and the remaining three patients had end-stage disease (deﬁned as Mondino/Foster stage 4)). Data were missing for one individual and
this patient was excluded from analysis.
cAll patients who were IIF were also DIF positive. There were no patients who were IIF positive in the absence of positive DIF studies.
dVisual acutiy represents a comparison of visual acuity in the better-seeing eye, after exclusion of other causes of reduced vision such as cataract,
glaucoma, age-related macular degeneration and diabetic retinopathy (n¼14, early-onset disease 5; established disease 9).
The early-onset disease group consisted of a younger cohort of patients with increased frequency of oral mucous membrane pemphigoid. DIF and IIF
refer to the proportion of patients who demonstrated the linear deposition of immunoglobulin G, A or complement (C3) along the basement membrane
zone or had measurable titres of immunoglobulin in the serum, respectively. Comparisons were undertaken with Fishers-exact test, Kendall’s t-b for rank
correlations and continuous variables were analysed by nonparametric tests (Mann–Whitney U-test).
Signiﬁcant P-values are in bold text.
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Eyeaccording to the presence or absence of clinically
identiﬁable conjunctival inﬂammation in at least one
eye. There was no signiﬁcant difference observed
between the ﬁrst and second 12 months follow-up
periods (data not shown). Moreover, despite the absence
of clinically detectable inﬂammation, progression of
disease occurred in 42% of patients according to the
Mondino system (Figure 4a, left panel), and 16 and 38%
of patients according to the Foster (Figure 4a, right panel)
system for each of the 12 months follow-up periods,
respectively.
Surgical intervention
At initial presentation to the specialist units, 32% (16/50)
of patients had previously undergone eyelid or fornix
reconstructive surgery by the referring hospital with the
Figure 3 Cross-sectional analysis of clinically detected conjunctival inﬂammation (a) and ocular staging using Mondino (b) and
Foster (c) systems in the worst eye at presentation, 12 months and 24 months follow-up in the EOD (&) and EstD groups (&).
Differences in the extent of conjunctival inﬂammation and stage of disease were compared between the two groups by rank correlation
using Kendal’s t-b. At 12 months follow-up, inﬂammation had resolved in the majority of eyes within both groups, and there were no
patients with severe inﬂammation. By 24 months, 30% of the remaining patients at the tertiary centres had residual inﬂammation not
responsive to treatment. Note that patients in the EstD had more advanced stage of disease compared with the EOD throughout the
follow-up period, but there was no difference in the progression rate (worsening of clinical stage of disease) between the two groups.
NB 14 patients had been referred back to their original hospital by 24 months and 1 had died. These patients have been excluded from
the analysis thereby accounting for the apparent increase in the percentage of patients at stage 1 and decrease in the percentage of
patients at stage 4 disease during the 12 and 24 months according to the Mondino staging system.
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(Po0.01; Supplementary Table 1). Although both groups
required oculoplastic surgical intervention at the tertiary
hospitals, this did not differ between the two groups, nor
during the ﬁrst and second 12 months follow-up periods.
Immunosuppression strategies
In all, 40% (20/50) of all patients were on immuno-
suppression at the time of referral. After ﬁrst
consultation, 36% (18/50) required initiation and 12%
Figure 4 Progression rates, deﬁned by worsening of either Mondino or Foster clinical staging of MMP, in the presence or absence of
clinically detectable conjunctival inﬂammation are shown in the upper composite (a). Note there was no signiﬁcant difference in
progression between eyes with clinically detectable inﬂammation or those that were seemingly uninﬂamed (Fishers exact test). The
percentage of patients requiring immunosuppression at presentation, following the ﬁrst follow-up (FU) clinic visit, 12 months and
24 months follow-up time points are shown in the lower b and c. Immunosuppression strategies were ranked according to the
hierarchy described by Rauz et al.
13 Overall, a signiﬁcant initiation or escalation in ‘strategic-step’ was required at the ﬁrst FU visit
(b; McNemar’s test), but this did not signiﬁcantly differ when the early onset (EoD) and established disease (EstD) groups were
compared (c; Kendal’s t-b). By 12 months follow-up, ﬁve patients stabilised on immunosuppression and were discharged back to their
originating hospitals, and similarly a further 10 between the 12 and 24 months follow-up.
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treatment representing a signiﬁcant overall ‘step-up’ on
the step ladder approach (P¼0.001; Figure 4b).
During the ﬁrst 12 months follow-up period, a further
30% (13/43) of patients required ‘step-up’ treatment
(P¼0.215; Figure 4b) equating to a total of 88%
(38/43) of patients requiring initiation or changes in
immunosuppression at presentation or during the ﬁrst
year of follow-up. By 24 months, immunosuppression could
be withdrawn in only one patient but no further escalation
in therapy was required. In all, 28% (14) patients had
stabilised and were discharged to the referring unit for
immunosuppression monitoring (Table 1). There was no
statistical difference between the requirements for
immunosuppression for each of the patient groups at each
o ft h et i m ep o i n t s( F i g u r e4 c ) .
The most commonly used drug by the referring unit
was Dapsone (26%, n¼13) followed by either
azathioprine or mycophenolate (8%, n¼4) with only one
patient on cyclophosphamide (2%, n¼1). The majority of
these patients were commenced on azathioprine or
mycophenolate (10%, n¼5) or switched to these drugs
from dapsone (10%, n¼5). Two further patients required
oral cyclophosphamide to control inﬂammation. By 12
months, an additional seven patients had initiated
cyclophosphamide therapy and this was either because
of the presence of exuberant inﬂammation (n¼3) not
adequately responding to less potent agents (two
requiring intravenous (i.v.) methylprednisolone) or there
was a requirement for an increase in immuno-
modulation before ocular or eyelid reconstructive
surgery. Resolution of inﬂammation occurred in two
patients who were ‘stepped down’ to less potent agents.
By 24 months, oral cyclophosphamide was withdrawn in
three patients (because of completing the maximum safe
duration of therapy of approximately 14 months, that is,
a cumulative dose (oral or i.v.) of o20g. The majority
(40%) of patients were maintained on either
mycophenolate or azathioprine. There was no statistical
difference in the immunosuppressive agents used
between the EOD and EstD groups. i.v. immunoglobulin
or biological agents were not administered during the
course of this study.
Adverse reactions to immunosuppression
Only 6 of the 38 patients that required
immunosuppression suffered from adverse effects.
Adverse events included one episode of anaemia
following dapsone; two patients reported headaches
after the use of azathioprine and one had induction
of hepatic enzymes; three patients developed
lymphopaenia while taking cyclophosphamide,
including one patient who developed respiratory failure
secondary to a combined cytomegalovirus and
Pneumocystis carinii pneumonitis, which resolved
following admission to the intensive care unit and
treatment with i.v. ganciclovir and oral cotrimoxazole.
Discussion
OcMMP is a bilateral sight-threatening disorder
characterised by progressive conjunctival cicatrisation
associated with corneal vascularisation and scarring. The
true incidence is not known although the outcome of a
recent British Ophthalmological Surveillance Unit study
suggests a minimum United Kingdom incidence of 0.7
per 1000000 population with a regional variance
exempliﬁed by 1.1 per million in Greater London and 1.8
per million in the West Midlands
20 (Radford et al,
unpublished data). MMP usually presents between 30
and 90 years of age, with a peak age of onset after 70
years.
3,7,19 Although disease progression is more
aggressive in younger patients,
13 the disease is lifelong
causing chronic discomfort, with 75% of patients
requiring immunosuppression to control inﬂammation
and limit disease progression.
8 The presence of extra-
ocular manifestations of MMP in approximately half of
our patients is consistent with other studies,
5,10 although
higher rates have been reported.
17
In this series, two disease phenotypes of OcMMP were
statistically deﬁned: (i) those with EOD who were
characterised as having less advanced disease stage but
signiﬁcantly greater conjunctival inﬂammation, and
(ii) those patients with EstD who had less clinically
identiﬁable inﬂammation but more advanced stage of
disease. Although 40% of the patient cohort were on
existing systemic immunosuppression, the majority of
patents required initiation or escalation in systemic
immunosuppression following either their ﬁrst clinic
visit, or during the ﬁrst year of follow-up in order to
control inﬂammation, facilitate corrective eyelid surgery
or prevent further progression in already advanced
disease states. Despite these measures, 20.8% of eyes
demonstrated disease progression during the ﬁrst 12
months and another 20.8% between 12 and 24 months;
and this progression was independent of the EOD or
EstD clinical phenotypes. These results indicate that
OcMMP may progress at any stage of disease,
7,8 and
more importantly, progression rates amongst eyes that
are clinically inﬂamed and those that are not do not
differ. These data endorse previously reported
literature,
4,10,21 and signify a molecular, ﬁbrotic process
independent of inﬂammation, which can be seen
clinically.
Accurately identifying early disease and documenting
progression presents difﬁculties. The staging systems
currently used are reliant on subjective assessment of
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EyeFigure 5 An algorithm highlighting clues to the diagnosis of OcMMP (ocular features, systemic involvement, autoimmune disease
associations), together with differential diagnoses for conjunctival scarring subdivided into ‘static or slowly progressive’ or ‘progressive’
aetiologies is shown. A putative model for early referral to tertiary care hospitals is also suggested. w, A subset develop autoantibody-
positive progressive conjunctival scarring similar to MMP; IF, immunoﬂuorescence; MMP, mucous membrane pemphigoid.
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Eyeconjunctival ﬁbrosis and obliteration of the inferior
fornix, with judgment of progression open to individual
interpretation. Information regarding horizontal
obliteration of the fornix by symblephara is not routinely
documented, precluding use of the proposed and
improved staging system described by Tauber.
22 In
addition, there is no standardised method for measuring
and documenting disease progression of the upper
fornix, when the disease is clearly not conﬁned to the
inferior conjunctival surface. Subsequent to this study,
we have designed and adopted the use of a validated
bespoke Fornix depth measurer to routine clinical
practise to enable quantiﬁcation of upper and lower
forniceal obliteration and to monitor disease
progression.
23
The difﬁculty lies not only in identifying early disease
and determining which patients may progress, but also
recognising when this is happening. ‘Activity’ and
‘damage’ indices have been validated and accepted for a
number of autoimmune conditions including systemic
lupus erythematosis and primary Sjo ¨gren’s syndrome.
24–27
These indices facilitate not only comparison of clinical
cohorts worldwide, but also inform clinical trials
speciﬁcally those targeting therapeutic intervention.
As such, we suggest that clearer strategies for
discriminating MMP disease ‘activity’ and ‘damage’
are necessary to afford a uniform language and
understanding when describing OcMMP phenotypes,
before molecular targeting and evaluation of novel
therapeutic approaches through randomised controlled
trials can be considered.
These difﬁculties in determining activity and
progression highlight the challenge in directing
appropriate therapy. The issue of suboptimal therapeutic
immuno-modulation of disease course has been widely
described.
4,5,9–11,28 We highlight a recalcitrant group of
patients with persistent mild or moderate inﬂamma-
tion in keeping with the ﬁndings of others.
10,11,13
Unfortunately, there is also a disease subset that either is
completely refractory to conventional immuno-
suppression or relapses despite initial success.
11 A few
isolated case reports indicate that ‘biological’ agents,
such as rituximab (anti-CD20) or inﬂiximab (anti-TNFa),
may be beneﬁcial in some of these patients, but as
randomised trials are lacking, funding for such treatment
in the United Kingdom prohibits regular use.
29–34 These
data re-emphasise the fact that the pathogenesis of
OcMMP is not resolved and strengthen the case for
further study of clinically involved and seemingly
uninvolved mucous membranes.
35–37
The reasons for a delay in presentation in our EstD
group are not clear. It is possible that the clinical features
or the severity of the disease may not have been
recognised until late, as early symptoms may have been
insidious and non-speciﬁc.
9,38 A variable duration of
disease and course have been described by others,
11 but
the true deﬁnition of early disease in the context of
OcMMP is not known. This may well lie under the 3 year
duration of symptoms statistically deﬁned in our cohort,
and this is particularly relevant if disease activity or
progression is initially either subtle or sub-clinical.
Experience in other more common autoimmune diseases,
such as rheumatoid arthritis, point to the clinician
actively pursuing identiﬁcation of early disease to enable
early therapeutic intervention in order to limit tissue
damage.
39 In the light of the potential for disease
progression in both early or late onset OcMMP disease
forms, irrespective of whether inﬂammation is clinically
detected or not, it may be prudent for ophthalmologists
to take precedence from the rheumatological concepts
for capturing early disease, and adopt a similar
approach.
Many of our patients travelled long distances to our
centres and this may represent a barrier to early tertiary
care of this rare disease, resulting in initiation of
suboptimal immunomodulation and/or surgery.
Stringent efforts to identify features characteristic of
OcMMP are necessary in order to avoid missing an early
diagnosis. Where local diagnosis or management is not
possible, or where the identiﬁcation of high risk features
including severe refractory inﬂammation or evidence of
progression is manifest, prompt referral of cases with
OcMMP to specialised tertiary centres is essential for
optimisation of immunosuppression aimed at limiting
long-term tissue damage. Furthermore, this may include
implementation of shared care pathways or stabilisation
of disease before discharge back to local referring centres,
as evident in many (28%) of our patients. We therefore
propose a referral algorithm as a putative model to help
educate these decisions and prompt early referral
(Figure 5).
Although our study is limited by its retrospective
nature and bias in our study population towards a more
severe clinical phenotype, a high proportion (48%) of
patients required initiation or a switch to more potent
immunosuppression following referral to our tertiary
centres. In addition, 28% of patients were eventually
returned to their local referring unit for monitoring after
stabilisation of disease. Most importantly, however, up to
42% of patients (irrespective of disease phenotype, early
or late) continued to demonstrate progressive
conjunctival scarring in the absence of clinically
detectable inﬂammation. A greater understanding of
disease pathology is required to facilitate earlier
recognition of disease, improved activity and damage
scores, and more accurate therapeutic targeting,
speciﬁcally for patients recalcitrant to existing
immunomodulatory therapy.
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